| D007231 |
Infant, Newborn |
An infant during the first 28 days after birth. |
Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants |
|
| D009157 |
Myasthenia Gravis |
A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. |
Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis |
|
| D002648 |
Child |
A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. |
Children |
|
| D002800 |
Cholinesterase Inhibitors |
Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. |
Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors |
|
| D004809 |
Ephedrine |
A phenethylamine found in EPHEDRA SINICA. PSEUDOEPHEDRINE is an isomer. It is an alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used for asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists. |
Ephedrine Hydrochloride,Ephedrine Renaudin,Ephedrine Sulfate,Erythro Isomer of Ephedrine,Sal-Phedrine,Ephedrine Erythro Isomer,Hydrochloride, Ephedrine,Renaudin, Ephedrine,Sal Phedrine,SalPhedrine,Sulfate, Ephedrine |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D000328 |
Adult |
A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. |
Adults |
|
| D018663 |
Adrenergic Agents |
Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters. |
Adrenergic,Adrenergic Agent,Adrenergic Drug,Adrenergic Neuron Agents,Adrenergic Release Inhibitors,Adrenergic Synthesis Inhibitors,Sympathetic Transmitter Releasers,Adrenergic Drugs,Adrenergic Effect,Adrenergic Effects,Adrenergic Neurohumor Depleters,Adrenergic Neuron Drugs,Adrenergics,Agent, Adrenergic,Agents, Adrenergic,Agents, Adrenergic Neuron,Depleters, Adrenergic Neurohumor,Drug, Adrenergic,Drugs, Adrenergic,Drugs, Adrenergic Neuron,Effect, Adrenergic,Effects, Adrenergic,Inhibitors, Adrenergic Release,Inhibitors, Adrenergic Synthesis,Neurohumor Depleters, Adrenergic,Neuron Agents, Adrenergic,Neuron Drugs, Adrenergic,Release Inhibitors, Adrenergic,Releasers, Sympathetic Transmitter,Synthesis Inhibitors, Adrenergic,Transmitter Releasers, Sympathetic |
|
| D020294 |
Myasthenic Syndromes, Congenital |
A heterogeneous group of disorders characterized by a congenital defect in neuromuscular transmission at the NEUROMUSCULAR JUNCTION. This includes presynaptic, synaptic, and postsynaptic disorders (that are not of autoimmune origin). The majority of these diseases are caused by mutations of various subunits of the nicotinic acetylcholine receptor (RECEPTORS, NICOTINIC) on the postsynaptic surface of the junction. (From Arch Neurol 1999 Feb;56(2):163-7) |
Congenital Slow-Channel Myasthenic Syndrome,Myasthenic Syndromes, Congenital, Slow Channel,Postsynaptic Congenital Myasthenic Syndrome,Presynaptic Congenital Myasthenic Syndrome,Slow-Channel Congenital Myasthenic Syndrome,Congenital Myasthenia,Congenital Myasthenia Gravis,Congenital Myasthenic Syndrome,Congenital Myasthenic Syndromes,Congenital Myasthenic Syndromes, Postsynaptic,Congenital Myasthenic Syndromes, Presynaptic,Congenital Slow-Channel Myasthenic Syndromes,Myasthenia Gravis, Congenital,Myasthenic Syndrome, Congenital, Slow-Channel,Postsynaptic Congenital Myasthenic Syndromes,Presynaptic Congenital Myasthenic Syndromes,Slow-Channel Congenital Myasthenic Syndromes,Congenital Myasthenias,Congenital Slow Channel Myasthenic Syndrome,Congenital Slow Channel Myasthenic Syndromes,Gravi, Congenital Myasthenia,Myasthenia, Congenital,Myasthenias, Congenital,Myasthenic Syndrome, Congenital,Slow Channel Congenital Myasthenic Syndrome,Slow Channel Congenital Myasthenic Syndromes,Syndrome, Congenital Myasthenic,Syndromes, Congenital Myasthenic |
|
| D020941 |
Myasthenia Gravis, Neonatal |
A disorder of neuromuscular transmission that occurs in a minority of newborns born to women with myasthenia gravis. Clinical features are usually present at birth or develop in the first 3 days of life and consist of hypotonia and impaired respiratory, suck, and swallowing abilities. This condition is associated with the passive transfer of acetylcholine receptor antibodies through the placenta. In the majority of infants the myasthenic weakness resolves (i.e., transient neonatal myasthenia gravis) although this disorder may rarely continue beyond the neonatal period (i.e., persistent neonatal myasthenia gravis). (From Menkes, Textbook of Child Neurology, 5th ed, p823; Neurology 1997 Jan;48(1):50-4) |
Antenatal Myasthenia Gravis,Neonatal Myasthenia Gravis,Myasthenia Gravis, Neonatal, Persistent,Myasthenia Gravis, Neonatal, Transient,Myasthenia Gravis, Persistent, Neonatal,Myasthenia Gravis, Transient, Neonatal,Neonatal Myasthenia Gravis, Persistent,Neonatal Myasthenia Gravis, Transient,Persistent Neonatal Myasthenia Gravis,Transient Neonatal Myasthenia Gravis,Myasthenia Gravis, Antenatal |
|
-transparent.png){kind=logo}
